Suggestions
Matt Donne, PhD
Operations @ Renasant Bio | Ph.D. @ UCSF | Advisor | Investor
Matt Donne, PhD, is the Director of Business Operations at 4:59 NewCo, a company affiliated with 5AM Ventures. He began this role in January 2023, as announced on his social media platforms.2
Educational Background
Donne completed his doctoral studies at the University of California, San Francisco (UCSF), where he focused on developmental and stem cell biology.14
Professional Experience
Before joining 4:59 NewCo, he held significant positions including:
- Chief of Staff and Head of Operations at Spring Discovery.5
- Involved in various roles that leverage his expertise in operations and management within the biotech sector.
Current Role
In his current position at 4:59 NewCo, Donne is responsible for overseeing business operations, which likely includes strategic planning, operational efficiency, and collaboration with other departments to drive the company's mission forward.13
Overall, Matt Donne combines a strong academic background with extensive operational experience in the biotech industry.
Highlights
We are less than 1 month away from our upcoming symposium, "Connecting the Dots: Bringing Cell and Gene Therapies to Patients," on August 29th. This event is a fundraising symposium to support Sickle Forward.
🔗 Free Student tickets: https://lnkd.in/gHbQvpej 🔗 Early industry tickets: https://lnkd.in/gPTkcsHr
Our goal from the get-go was ambitious: to gather world-class academics, venture capitalists, regulatory experts, and industry leaders to share their experiences in advancing cell and gene therapies from the lab to patients.
The lineup so far is incredible:
Unlocking the Potential of Your Project Kole Roybal- Associate Professor at University of California, San Francisco Director of the Parker Institute for Cancer Immunotherapy, and co-founder of Arsenal Biosciences, Inc. Daniel Bryan Goodman- Post-Doc in the Bluestone, Roybal, and Marson lab. Scientific Advisor to Manifold Bio, Retro Biosciences, and Arsenal Biosciences, Inc. Lexi Rovner- Co-Founder of 64x Bio
Funding the Future of CGTs Michelle Ho, 5AM Ventures Jonathan Sockolosky- Curie.Bio
Regulating Innovation CDRH representative CDER/CBER representative Yoshiko Stowell, PhD, RAC, PMP Stowell- Head of Regulatory, Kenai Therapeutics
Navigating the Ship Martin Borch Jensen- co-founder, CSO, Gordian Biotechnology Krishnan Viswanadhan, Pharm.D- President/COO, BeBio Sharon Benzeno- CCO, Adaptive Biotechnologies Corp. Bio Andrew Allen- Co-Founder/CEO, Gritstone bio
We are dedicated to creating a blend of academic and industry perspectives. We’re offering free tickets to students through an application process, as well as reduced-price “Industry Early Backer” tickets.
🔗 Student ticket application: https://lnkd.in/gHbQvpej 🔗 Early industry tickets: https://lnkd.in/gPTkcsHr
A special shoutout and THANK YOU to 5AM Ventures for being our first sponsor and Tim L., Kale Frank, and Pete Sletteland at SVB for generously donating their beautiful event space in downtown San Francisco for this event.
Please consider joining us for an amazing afternoon dedicated to learning and sharing. Feel free to DM with any questions.
#cellandgenetherapy #entrepreunership #vc #biotech #startups
Current industry supporters of the Luke Timmerman Traverse supporting Sickle Forward include HemoTypeSC, Agios Pharmaceuticals, Vertex Pharmaceuticals, bluebird bio, Pfizer, CRISPR Therapeutics, Evercore, Beam Therapeutics, Fulcrum Therapeutics, Browne Consulting, and Rocket Pharmaceuticals, Goodwin, BioMedomics, Inc.,
We’re thrilled to finally share our upcoming symposium, "Connecting the Dots: Bringing Cell and Gene Therapies to Patients," on August 29th. This event is a fundraising symposium to support Sickle Forward.
Our goal from the get-go was ambitious: to gather world-class academics, venture capitalists, regulatory experts, and industry leaders to share their experiences in advancing cell and gene therapies from the lab to patients.
The lineup so far is incredible:
Unlocking the Potential of Your Project Kole Roybal- Associate Professor at University of California, San Francisco Director of the Parker Institute for Cancer Immunotherapy, and co-founder of Arsenal Biosciences, Inc. Daniel Bryan Goodman- Post-Doc in the Bluestone, Roybal, and Marson lab. Scientific Advisor to Manifold Bio, Retro Biosciences, and Arsenal Biosciences, Inc. Lexi Rovner- Co-Founder of 64x Bio
Funding the Future of CGTs 5AM Ventures- Michelle Ho Curie.Bio- Jonathan Sockolosky
Regulating Innovation CDRH representative CDER/CBER representative CDO/reg representative
Navigating the Ship Martin Borch Jensen- co-founder, CSO, Gordian Biotechnology Krishnan Viswanadhan, Pharm.D- President/COO, BeBio Sharon Benzeno- CCO, Adaptive Bio Andrew Allen- Co-Founder/CEO, Gritstone bio
We are dedicated to creating a blend of academic and industry perspectives. Due to limited space, we’re offering free tickets to students through an application process, as well as reduced-price “Industry Early Backer” tickets.
🔗 Student ticket application: https://lnkd.in/gHbQvpej 🔗 Early industry tickets: https://lnkd.in/gPTkcsHr
A special shoutout and THANK YOU to 5AM Ventures for being our first sponsor. We are seeking additional corporate sponsors to help make this event successful. Feel free to DM with any questions.
Please join us for an amazing afternoon dedicated to learning and sharing together.
#entrepreneurship #VC #bayarea #CellAndGeneTherapy #Biotech #SickleForward #Symposium #CGT #Innovation #Healthcare
Current industry supporters of the Luke Timmerman Traverse supporting Sickle Forward include HemoTypeSC, Agios Pharmaceuticals, Vertex Pharmaceuticals, bluebird bio, Pfizer, CRISPR Therapeutics, Evercore, Beam Therapeutics, Fulcrum Therapeutics, Browne Consulting, and Rocket Pharmaceuticals
